{"title":"Alterations of Monoaminergic Systems in Alzheimer's Disease: A Traditional Review","authors":"Raviye ÖZEN KOCA, Z. I. SOLAK GÖRMÜŞ, H. Solak","doi":"10.5336/medsci.2022-89011","DOIUrl":null,"url":null,"abstract":"Alzheimer’s disease (AD) is an age-related, neurodegenerative disease with characteristic clinical and pathological features. The death rate from AD was exacerbated by the coronavirus disease 2019 pandemic in 2020. The most common neuropathological findings are extraneuronal senile plaques and intraneuronal neurofibrillary tangles. AD is a multisystemic disease that affects many neuronal structures, including monoaminergic systems. Functional changes in neurotransmitters are closely related to the pathophysiology of AD. It is known that many neurotransmitters such as acetylcholine decrease as a result of loss of neuronal synapses and neuronal death. In the monoaminergic system, basically, the substantia nigra nucleus providing the dopaminergic innervation, the dorsal raphe nucleus providing the serotonergic innervation, the locus ceruleus nucleus providing the noradrenergic innervation, and the tuberomamillar nucleus providing the histaminergic innervation are exposed to significant degeneration in AD. There are changes in the levels of relevant neurotransmitters in the regions projected from these nuclei. Combined therapy (cognitive enhancing treatments, drugs to treat neuropsychiatric symptoms, disease-modifying therapies) important to reduce behavioral abnormalities and effectively restore cognitive functions in AD patients. Treatment strategies for AD require understanding the molecular mechanism behind the monoaminergic system. With this traditional review, we aim to discuss in detail the changes that occur in the monoaminergic system, especially in dopamine, noradrenaline, serotonin and histamine mechanisms in AD, and present a perspective on this issue. As a result;more studies in humans and animal models are needed to better understand the signaling mechanism of the monoaminergic system and the effects of monoaminergic receptors. Thus, the development of new treatment strategies for AD will accelerate. © 2022 by Türkiye Klinikleri.","PeriodicalId":49403,"journal":{"name":"Turkiye Klinikleri Tip Bilimleri Dergisi","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkiye Klinikleri Tip Bilimleri Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5336/medsci.2022-89011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
阿尔茨海默病单胺能系统的改变:传统综述
阿尔茨海默病(AD)是一种与年龄相关的神经退行性疾病,具有独特的临床和病理特征。2020年2019冠状病毒大流行加剧了阿尔茨海默病的死亡率。最常见的神经病理表现是神经元外老年斑和神经元内神经原纤维缠结。AD是一种多系统疾病,影响许多神经元结构,包括单胺能系统。神经递质的功能改变与AD的病理生理密切相关。众所周知,许多神经递质如乙酰胆碱的减少是神经元突触丧失和神经元死亡的结果。在单胺能系统中,基本上,提供多巴胺能神经支配的黑质核,提供血清素能神经支配的中背核,提供去甲肾上腺素能神经支配的蓝斑核,以及提供组胺能神经支配的结节状核在AD中暴露于显著变性。在这些核投射的区域中,相关神经递质的水平发生了变化。联合治疗(认知增强治疗,治疗神经精神症状的药物,疾病修饰治疗)对减少AD患者的行为异常和有效恢复认知功能很重要。阿尔茨海默病的治疗策略需要了解单胺能系统背后的分子机制。通过这一传统的回顾,我们旨在详细讨论单胺能系统,特别是多巴胺、去甲肾上腺素、血清素和组胺在AD中的作用机制的变化,并提出这一问题的观点。因此,需要更多的人类和动物模型研究来更好地了解单胺能系统的信号传导机制和单胺能受体的作用。因此,新的AD治疗策略的开发将会加速。©2022 by rkiye Klinikleri。
本文章由计算机程序翻译,如有差异,请以英文原文为准。